Abstract
Background Although obesity is a recognized risk factor of atrial fibrillation (AF), the mechanisms are not fully understood. Thus, we aimed to identify the potential mediators between body mass index (BMI) and AF.
Methods We conducted a two-sample Mendelian randomization (MR) analysis using publicly available summary-level data from genome-wide association studies. Univariable MR analyses were applied to identify potential mediators, and then the multivariable MR analyses were conducted to explore the mediated roles of circulating cytokines, metabolic markers and comorbidities in the association between BMI and AF.
Results This MR study found a significant causal association between BMI and AF (OR=1.41, 95%CI=1.33-1.50; P<0.001), which was attenuated to 1.21 (95%CI=1.03-1.43) after being adjusted for leptin, in which 48.78% excess risk was mediated. After further adjustment for leptin and sleep apnoea or coronary heart disease, the association was attenuated to null (adjusted for leptin and sleep apnoea: OR=1.05, 95%CI=0.85-1.30; adjusted for leptin and coronary heart disease: OR=1.08, 95%CI=0.90-1.30), resulting in 87.80% and 80.49% excess risk being mediated, respectively.
Conclusion These results identified an important mediated role of leptin, particularly for individuals with sleep apnoea or coronary heart disease, providing some clues for the underlying mechanisms behind the impact of obesity on AF risk.
Funding Natural Science Foundation of Fujian Province (grant no. 2022J01706) and the Start-up Fund for high-level talents of Fujian Medical University (XRCZX2021026).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Natural Science Foundation of Fujian Province (grant no. 2022J01706) and the Start-up Fund for high-level talents of Fujian Medical University (XRCZX2021026) to Dr. Wuqing Huang. The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
↵* Share the senior authorship.
Data Availability
All raw data are available in the public repository IEU open gwas project (https://gwas.mrcieu.ac.uk/)
Abbreviations
- AF
- Atrial fibrillation
- CRP
- C-reactive protein
- BMI
- body mass index
- MR
- Mendelian randomization
- GWASs
- Genome-Wide Association Studies
- LDL-C
- low-density lipoprotein cholesterol
- HDL-C
- high-density lipoprotein cholesterol
- TC
- total cholesterol
- TG
- triglycerides
- GIANT
- Genetic Investigation of ANthropometric Traits
- SNPs
- single nucleotide polymorphisms
- IVW-MR
- inverse-variance weighted mendelian randomization
- PERM
- percentage of excess risk mediated
- OR
- odds ratio
